FDA greenlights skin/eye drug advisors through 2028
Published Date: 10/1/2026
Notice
Summary
The FDA is renewing the Dermatologic and Ophthalmic Drugs Advisory Committee for two more years, keeping it active until October 7, 2028. This committee helps make sure skin and eye medicines are safe and effective, affecting patients, doctors, and drug makers. No new costs or big changes, just a green light to keep the expert advice coming!
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2026-20139, Aluminum Foil From Armenia, Brazil, Oman, Russia, and Turkey; Institution of Five-Year Reviews
The U.S. International Trade Commission is checking if aluminum foil imports from Armenia, Brazil, Oman, Russia, and Turkey still need extra duties to protect American businesses. They want to know if stopping these duties would hurt U.S. foil makers. People involved have until November 2, 2026, to share their thoughts, so the Commission can decide what’s best.
Next: 2026-20142, Advisory Committee; Antimicrobial Drugs Advisory Committee; Renewal
The FDA is renewing its Antimicrobial Drugs Advisory Committee for two more years, keeping it active until October 7, 2028. This committee helps make sure medicines fighting infections are safe and effective. Doctors, scientists, and the public all benefit from this continued expert advice, with no new costs announced.